- adjuvant therapy
- ado-trastuzumab emtansine (Kadcyla or T-DM1)
- adriamycin and cyclophosphamide (AC)
- adriamycin, cyclophosphamide, and taxol (AC-T)
- adriamycin, cyclophosphamide, taxol, and herceptin (AC-TH)
- anastrozole (Arimidex)
- anthracycline
- Arimidex (anastrozole)
- aromatase inhibitor (AI)
- axillary dissection
- axillary lymph node
- axillary lymph node dissection
- benign
- benign breast disease (mammary dysplasia)
- bilateral cancer
- bilateral prophylactic mastectomy
- biopsy
- biopsy specimen
- BRCA1
- breast cancer
- breast carcinoma in situ
- breast density
- breast duct
- breast implant
- breast lobule
- breast reconstruction
- breast tomosynthesis
- breast-conserving surgery
- breast-sparing surgery
- chemotherapy
- clinical study
- clinical trial
- clinical trial phase
- computed tomography scan (CT scan)
- conventional therapy
- conventional treatment
- core biopsy
- cyclophosphamide
- deep inferior epigastric perforators (DIEP flap)
- DIEP flap (deep inferior epigastric perforators)
- differentiation
- digital mammography
- distant metastasis
- docetaxel (Taxotere)
- drain
- ductal carcinoma
- ductal carcinoma in situ (DCIS)
- early-stage breast cancer
- end-stage cancer
- estrogen blocker
- estrogen receptor (ER)
- estrogen receptor negative (ER-)
- estrogen receptor positive (ER+)
- estrogen receptor test
- external-beam radiation therapy
- extremely dense breast tissue
- fatty breast tissue
- fine-needle aspiration biopsy (FNA biopsy)
- fluorescence in situ hybridization (FISH)
- gene
- genetic
- genetic counseling
- HER2 Positive (HER2+)
- HER2/neu
- HER2/neu test
- Herceptin
- hereditary breast and ovarian cancer syndrome (HBOC syndrome)
- heterogeneously dense breast tissue
- high grade
- human epidermal growth factor receptor 2 negative (HER2 negative)
- Ibrance (palbociclib)
- imaging procedure
- in situ
- infusion
- integrative medicine
- intermediate grade
- intravasion
- intravenous (IV)
- intravenous (IV) chemotherapy
- invasive breast cancer
- invasive ductal carcinoma (IDC)
- invasive lobular carcinoma (ILC)
- isosulfan blue
- Kadcyla (ado-trastuzumab emtansine or T-DM1)
- Kadcyla (T-DM1)
- laboratory test
- lapatinib (Tykerb)
- late-stage cancer
- latissimus dorsi flap (lat flap)
- lesion
- leukocyte
- levels of evidence
- lidocaine
- lifetime risk
- linear accelerator
- lobular carcinoma
- lobular carcinoma in situ (LCIS)
- local cancer
- local therapy
- locally recurrent cancer
- long-term side effect
- low grade
- lumpectomy
- lymph (lymphatic fluid)
- lymph gland (lymph node)
- lymph node dissection
- lymph node drainage
- lymph node mapping (lymphatic mapping)
- lymph vessel (lymphatic vessel)
- lymphatic basin
- lymphatic system
- lymphedema
- lymphocyte
- magnetic resonance imaging (MRI)
- malignancy
- malignant
- MammaPrint
- mammary
- mammary gland (breast)
- mammogram
- mammography
- margin
- mass
- mastectomy
- maternal
- mean
- mean survival
- medial supraclavicular lymph node
- median
- median overall survival
- medical oncologist (MO)
- medication
- medicine
- mega-voltage linear accelerator
- meiosis
- menopausal hormone therapy (MHT)
- menopause
- menorrhagia
- menstrual cycle
- menstrual period
- meta-analysis
- metallic
- metastasis
- metastasize
- metastatic
- MeV linear accelerator
- microcalcification
- microenvironment
- micrometastasis
- microscope
- milk duct
- milk duct
- minimally invasive surgery
- mitosis
- T-DM1 (ado-trastuzumab emtansine or Kadcyla)
- Taxotere (docetaxel)
- tumor grade
